A 69-year-old woman with morbid obesity lost 90 pounds (over 30% of her body weight) over 65 weeks on semaglutide, exceeding average clinical trial results, with her hypertension and glucose levels also normalizing.
90 lb lost (>30% body weight)Over 65 weeks of semaglutide treatment with zero side effects — exceeding the ~15-17% average weight loss seen in large clinical trials
What the researchers found
A 69-year-old female with morbid obesity (starting BMI 47, weight 241 lb) lost 90 lb (over 30% of body weight) over 65 weeks of semaglutide treatment. This weight loss exceeded the average reduction reported in previous large-scale studies. The patient experienced no side effects. Additionally, her hypertension resolved and her glucose levels normalized during treatment.
Why it matters
Large clinical trials like STEP have shown semaglutide produces average weight loss of about 15-17% of body weight. This case demonstrates that some individuals can achieve dramatically greater results — over 30% — suggesting there may be subpopulations of 'super-responders' to GLP-1 receptor agonist peptide therapy. Understanding why some patients respond so well could help personalize obesity treatment.
How the study worked
This is a single-patient case report documenting the clinical outcomes of semaglutide treatment in a 69-year-old woman with morbid obesity and hypertension. Weight, blood pressure, and glucose levels were monitored over the 65-week treatment period. The specific semaglutide formulation and dosing details were not provided in the abstract.
What this study cannot tell us
As a single-patient case report, this represents the lowest level of clinical evidence. The results cannot be generalized to other patients. The specific semaglutide dose and titration schedule are not detailed in the abstract. No information is provided about diet, exercise, or other lifestyle changes that may have contributed to the outcome. There is no long-term follow-up data on weight maintenance after achieving this loss.
How to read the evidence
This is a single-patient case report, the lowest tier of clinical evidence. While the results are striking, they represent one individual's experience and cannot be generalized. Case reports are valuable for documenting exceptional outcomes but do not establish efficacy or safety for the broader population.
When this study was published
Published in 2025, this is a very recent case report reflecting current clinical use of semaglutide for weight management.
The bigger picture
GLP-1 receptor agonist peptides like semaglutide have transformed obesity treatment, but response varies significantly between patients. Case reports documenting exceptional responses help map the range of possible outcomes and may help identify factors that predict who will benefit most. The concurrent resolution of hypertension and glucose dysregulation also reinforces the systemic metabolic benefits of these peptide therapies beyond weight loss alone.
Questions still open
- What factors — genetic, metabolic, or behavioral — enabled this patient to lose more than double the average weight reported in semaglutide clinical trials?
- Will this patient maintain the weight loss long-term, and would stopping semaglutide lead to weight regain as seen in some trial data?
Common questions
Is losing 30% of body weight on semaglutide typical?
Why did the patient's blood pressure and blood sugar improve along with weight loss?
Read the original research
Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.
Cureus, 17(2), e79254
Citation
Danish, Sidra; Dogra, Vallabh; Rauf, Uzma; Saghir, Maryam; Aslam, Nadia. (2025). Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.. Cureus, 17(2), e79254. https://doi.org/10.7759/cureus.79254